CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation-Reference-Cited by-同舟云学术

CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation

Published:2018-07-01 Issue:11 Volume:19 Page:895-903
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Yang Lin¹,de Winter Brenda CM²,van Schaik Ron HN³,Xie Rui-Xiang¹,Li Yi⁴,Andrews Louise M²,Shuker Nauras²,Bahmany Soma²,Koch Birgit²,van Gelder Teun²⁵,Hesselink Dennis A⁵

Affiliation:

1. Department of Pharmacy, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, PR China

2. Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

3. Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

4. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, PR China

5. Department of Internal Medicine, Division of Nephrology & Transplantation, Rotterdam Transplant Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Abstract

Aim: To investigate the association between donor CYP3A5 and ABCB1 polymorphisms and tacrolimus (Tac)-induced nephrotoxicity and renal function in kidney transplant recipients. Methods: The CYP3A5 6986A>G and ABCB1 3435C>T polymorphisms were determined in 237 recipients and donors. Results: There was no significant association between Tac-related nephrotoxicity and donor CYP3A5 and ABCB1 genotype. The donor ABCB1 3435C>T polymorphism was associated with estimated glomerular filtration rate on day 7 and month 1. The combined donor–recipient ABCB1 genotype (3435C>T polymorphism) was significantly related with estimated glomerular filtration rate on day 3 and 7 in univariate analysis. However, these differences were no longer statistically significant in multivariate analysis. Conclusion: A genetic analysis of ABCB1 and CYP3A5 of kidney transplant donors is not helpful to improve renal transplant outcomes.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2018-0066

Reference40 articles.

1. Tacrolimus

2. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation

3. Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity

4. Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients

5. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP3A5 Expressor Genotype of the Transplanted Kidney Increases the Risk of Preterm Graft Loss and Acute Rejection;Nephron;2023

2. Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients;Annals of Transplantation;2022-06-15

3. CYP3a5 Genetic Polymorphism in Chinese Population With Renal Transplantation: A Meta-Analysis Review;Transplantation Proceedings;2022-04

4. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients;British Journal of Clinical Pharmacology;2021-03-19

5. Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome;Pharmacogenomics;2019-10